Description: bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.
Home Page: www.bioaffinitytech.com
BIAF Technical Analysis
22211 West Interstate 10
San Antonio,
TX
78257
United States
Phone:
210 698 5334
Officers
| Name | Title |
|---|---|
| Ms. Maria Zannes J.D. | Founder, Pres, CEO & Director |
| Dr. Vivienne I. Rebel M.D., Ph.D. | Exec. VP and Chief Medical & Science Officer |
| Mr. Michael Edwards CPA, M.B.A. | Chief Financial Officer |
| Mr. Xavier T. Reveles M.S. | VP of Operations |
| Mr. Timothy P. Zannes J.D. | Exec. VP, Sec. & Gen. Counsel |
| Dr. William Bauta Ph.D. | Sr. VP of Therapeutics |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.3353 |
| Price-to-Sales TTM: | 6847.0483 |
| IPO Date: | 2022-09-01 |
| Fiscal Year End: | December |
| Full Time Employees: | 11 |